NasdaqGS:BNTXBiotechs
Is Goldman’s Oncology Upgrade Altering The Investment Case For BioNTech’s Pipeline-Driven Future (BNTX)?
Goldman Sachs recently upgraded BioNTech SE to Buy, highlighting the company’s position in next-generation immuno-oncology and antibody-drug conjugates, with key oncology data expected in 2026.
This endorsement reinforces BioNTech’s shift from its Covid-focused profile toward building a broader oncology franchise powered by its mRNA and antibody platforms.
Next, we’ll examine how Goldman Sachs’ confidence in BioNTech’s oncology pipeline could influence the company’s long-term investment...